Fig. 5.
Overall Treatment Effect (OTE) rating for (A) patient-rated general health-related quality of life (HRQoL) and (B) physician-rated GI symptoms after conversion to EC-MPS compared to baseline. EC-MPS converted group significantly improved in patient- and physician-rated OTE compared to MMF continued group (all P<0.001).
EC-MPS, enteric-coated mycophenolate sodium; MMF, mycophenolate mofetil.